Abstract: OBJECTIVE To provide the basis for clinical guidance of age-related macular degeneration(AMD) drugs, the efficacy of conpercept and ranibizumab against AMD was compared by systematic review. METHODS Relevant randomized control trials about conpercept versus ranibizumab were identified by searching electronic databases including Pubmed, The Cochrane Library, Web of Science, Wanfang data, CNKI, CBM and VIP Database. RevMan 5.3 software was used for relevant index data analysis. Random and fixed effect models were employed to evaluate heterogeneity, funnel plots were also used to detect the publication bias. RESULTS A total of 15 studies, involving 940 patients were included of meta-analysis. There was no difference of central macular of retinal thickness(CRT)WMD=-4.78, 95%CI(-11.63, 2.07), P=0.17, and best corrected visual acuity(BCVA)WMD=-0.02, 95%CI(-0.03, 0.00), P=0.07 between the 2 groups, while leakage area of corneal neovascularization (CNV) in conpercept group was better than ranibizumab groupWMD=-0.98, 95%CI(-1.22, -0.73), P<0.000 01, the difference was significant. CONCLUSION Conpercept and ranibizumab have the similar therapeutic effect on AMD. They both can improve BCVA, reduce CRT and inhibit the leakage area of CNV, while conpercept has a certain therapeutic advantage in controlling the leakage area of CNV.